Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of pharmaceutical products. The company is headquartered in The Woodlands, Texas.
| Revenue (TTM) | $41.47M |
| Gross Profit (TTM) | $35.67M |
| EBITDA | $-54.02M |
| Operating Margin | -3835.00% |
| Return on Equity | -40.20% |
| Return on Assets | -14.30% |
| Revenue/Share (TTM) | $0.11 |
| Book Value | $0.39 |
| Price-to-Book | 5.91 |
| Price-to-Sales (TTM) | 25.11 |
| EV/Revenue | 21.73 |
| EV/EBITDA | 16.57 |
| Quarterly Earnings Growth (YoY) | -63.40% |
| Quarterly Revenue Growth (YoY) | -97.60% |
| Shares Outstanding | $444.96M |
| Float | $218.99M |
| % Insiders | 1.12% |
| % Institutions | 83.71% |
Volatility is currently expanding
Lexicon Pharmaceuticals NASDAQ: LXRX reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III SONATA-HCM trial and outlined plans to resubmit a new drug application for ZYNQUISTA in type 1 diabetes during the fourth quarter.
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.01 per share a year ago.
Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 NDA resubmission activities for ZYNQUISTA ® in type 1 diabetes nearing completion Phase 1 clinical development of LX9851 ongoing by Novo Nordisk Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2026, and provided an update on key corporate milestones and accomplishments. “Lexicon continued to make strong progress during the second quarter, with the refinement of our strategy and sharpening of our focus beginning to bear fruit across our business,” said Mike Exton, Ph.D.
THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.
Study substantially exceeded enrollment target of 500 patients Topline results anticipated in Q1 2027 THE WOODLANDS, Texas, July 27, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that randomization of patients has been completed in the pivotal Phase 3 “SOtaglifloziN in Patients with SymptomATic obstructive And non-obstructive Hypertrophic CardioMyopathy (SONATA-HCM)” clinical trial evaluating sotagliflozin in patients with non-obstructive (nHCM) and obstructive (oHCM) hypertrophic cardiomyopathy. The study substantially exceeded its enrollment target of 500 patients across more than 130 sites in 20 countries.
Lexicon advances sotagliflozin into new indications while its obesity and pain programs progress, setting the stage for multiple pipeline milestones.
Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groups Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groups
THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 2:00 p.m. ET in New York City.
THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on May 19, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LXRX and any ticker you trade — then tracks every position and per-strategy win rate.
